Windlas Biotech Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/lqji5x1vmhcgoef52yo05uam.pdf

Key Takeaways


Injectable Facility: The Central Bet

Hitesh Windlass: "Even in India business, the gross margin for injectable will be very high than gross margin for oral solids. So from a financial perspective, this is all -- it's a win-win."

Trade Generics & Institutional: The Growth Engine

Hitesh Windlass: "Our mantra has been Affordable, Accessible and Authentic drugs. So this is where we are. We are in the middle of this opportunity and we have to make the most of it."

CDMO: Steady but Lumpy

Hitesh Windlass: "If you do not have IP, then what are you selling? You're only selling capacity, right? And so when you are only selling capacity and your customer is providing you the material, you're just converting so it's job work; then you cannot have this kind of EBITDA margins."

Exports: Early Innings

Hitesh Windlass: "This is the reason why export is a little bit fag ended. And however, we have already we are on the -- we have done our product selection, we are working on taking all the steps that are required to expedite wherever we can."

Costs, Margins & Balance Sheet


Capacity Expansion & Inorganic Strategy

Hitesh Windlass: "For us the most important thing right now is that we have one of the strongest balance sheets, we have a strong growth momentum and we are being very choosy on the inorganic side."

Guidance & Commitments

CommitmentSpecificsTimeline
Injectable customer auditsLarge customers have scheduled audits of injectable facilityQ4 FY25
Injectable revenue startSome revenue will clock in Q4, then crossover breakevenQ4 FY25 and beyond
ROCE floorStay around 25% and above at all timesOngoing
Plant-6 capex detailsManagement will comment on layout, machinery, and capex planBy end-of-March call
Revenue capacity targetReach ₹1,000 crores total capacity with Plant-6 build-outNo date; Plant-6 in planning stage
Injectable exportsStability batches, dossier filing, and approvals in progress1.5-2 years from filing for approvals

Key Metrics

MetricQ3 FY25
Revenue₹195 cr, +20% YoY
9M FY25 revenue₹557.2 cr, +21% YoY
EBITDA₹24.6 cr, +21% YoY; margin 12.6%
9M FY25 EBITDA₹68.6 cr, +22% YoY; margin 12.3%
PAT₹15.6 cr, +3% YoY
9M FY25 PAT₹44.7 cr, +9% YoY
CDMO vertical revenue₹135.7 cr, +8% YoY
Trade Generics & Institutional revenue₹49.6 cr, +74% YoY
Exports revenue₹9.7 cr, +19% YoY
9M FY25 CDMO revenue₹407.9 cr, +15% YoY
9M FY25 Trade Generics & Institutional revenue₹126.6 cr, +44% YoY
9M FY25 Exports revenue₹22.6 cr, +23% YoY
Depreciation increase (injectables)₹3.6 cr in Q3, almost entirely due to injectable facility
ROCE (including injectables)27%
ROCE (excluding injectables)38%
Investment in injectables~₹75 cr
Oral solids and liquids capacity~₹800 cr revenue potential, excluding injectables
Cash and investments>₹200 cr in mutual funds, ~₹15-16 cr in fixed deposits